Output trends, characteristics, and measurements of three megavoltage radiotherapy linear accelerators.

The purpose of this study is to characterize and understand the long-term behavior of the output from megavoltage radiotherapy linear accelerators. Output trends of nine beams from three linear accelerators over a period of more than three years are reported and analyzed. Output, taken during daily warm-up, forms the basis of this study. The output is measured using devices having ion chambers. These are not calibrated by accredited dosimetry laboratory, but are baseline-compared against monthly output which is measured using calibrated ion chambers. We consider the output from the daily check devices as it is, and sometimes normalized it by the actual output measured during the monthly calibration of the linacs. The data show noisy quasi-periodic behavior. The output variation, if normalized by monthly measured "real' output, is bounded between ± 3%. Beams of different energies from the same linac are correlated with a correlation coefficient as high as 0.97, for one particular linac, and as low as 0.44 for another. These maximum and minimum correlations drop to 0.78 and 0.25 when daily output is normalized by the monthly measurements. These results suggest that the origin of these correlations is both the linacs and the daily output check devices. Beams from different linacs, independent of their energies, have lower correlation coefficient, with a maximum of about 0.50 and a minimum of almost zero. The maximum correlation drops to almost zero if the output is normalized by the monthly measured output. Some scatter plots of pairs of beam output from the same linac show band-like structures. These structures are blurred when the output is normalized by the monthly calibrated output. Fourier decomposition of the quasi-periodic output is consistent with a 1/f power law. The output variation appears to come from a distorted normal distribution with a mean of slightly greater than unity. The quasi-periodic behavior is manifested in the seasonally averaged output, showing annual variability with negative variations in the winter and positive in the summer. This trend is weakened when the daily output is normalized by the monthly calibrated output, indicating that the variation of the periodic component may be intrinsic to both the linacs and the daily measurement devices. Actual linac output was measured monthly. It needs to be adjusted once every three to six months for our tolerance and action levels. If these adjustments are artificially removed, then there is an increase in output of about 2%-4% per year.

Dosimetric investigation of high dose rate, gated IMRT.

Increasing the dose rate offers time saving for IMRT delivery but the dosimetric accuracy is a concern, especially in the case of treating a moving target. The objective of this work is to determine the effect of dose rate associated with organ motion and gated treatment using step-and-shoot IMRT delivery. Both measurements and analytical simulation on clinical plans are performed to study the dosimetric differences between high dose rate and low dose rate gated IMRT step-and-shoot delivery. Various sites of IMRT plans for liver, lung, pancreas, and breast cancers were delivered to a custom-made motorized phantom, which simulated sinusoidal movement. Repeated measurements were taken for gated and nongated delivery with different gating settings and three dose rates, 100, 500, and 1000 MU/min using ion chambers and extended dose range films. For the study of the residual motion effect for individual segment dose and composite dose of IMRT plans, our measurements with 30%-60% phase gating and without gating for various dose rates were compared. A small but clinically acceptable difference in delivered dose was observed between 1000, 500, and 100 MU/min at 30%-60% phase gating. A simulation is presented, which can be used for predicting dose profiles for patient cases in the presence of motion and gating to confirm that IMRT step-and-shoot delivery with gating for 1000 MU/min are not much different from 500 MU/min. Based on the authors sample plan analyses, our preliminary results suggest that using 1000 MU/Min dose rate is dosimetrically accurate and efficient for IMRT treatment delivery with gating. Nonetheless, for the concern of patient care and safety, a patient specific QA should be performed as usual for IMRT plans for high dose rate deliveries.

When and how to treat an IMRT patient on a second accelerator without replanning?

When a linear accelerator is unavailable for treatment, a clinical decision is imminent regarding whether a patient should be treated on a linear accelerator other than the machine the patient was scheduled on, or whether treatment should be postponed until the original Linac becomes available. This work investigates the feasibility of switching patients to different accelerators for intensity-modulated radiation therapy (IMRT). We have performed Monte Carlo simulations of photon beams from different Linac models and vendors. Prostate and head and neck (H&N) treatment plans for Siemens Primus, Primart, and Varian 21EX accelerators are studied in this work. Dose distributions for given plans are recalculated using different beam data with the same nominal energy from different Linacs. We have compared dose-volume histograms (DVHs) and the maximum, the minimum, and the mean doses to the target and critical structures because of switching accelerators. In the process of switching a treatment plan to a different accelerator, issues exist, including optimum penumbra compensation, dose distribution at the boundary of target and critical structures, and multileaf collimator (MLC) leaf-width effects, which need to be considered and verified with measurements. Our Monte Carlo simulation results confirm that, for the cases we tested, the dose received by 95% of the planning target volume differs by 0.2% to 1.5% between Siemens Primus and Varian 21EX Linacs. The discrepancy is within our clinical acceptance criteria of 3% for IMRT treatments. In making the final decision on whether to switch machines or not, the tumor control probabilities (TCPs) based on a linear-quadratic model are compared. Based on the analyses performed in this work, it is therapeutically more beneficial to switch a patient to a different machine than to postpone a treatment until the original machine is available, especially for fast-growing tumors such as H&N cancers.

On beam quality and flatness of radiotherapy megavoltage photon beams.

Ratio of percentage depth dose (PDD) at two depths, PDD at a depth of 10 cm (PDD10), and beam flatness are monitored regularly for radiotherapy beams for quality assurance. The purpose of this study is to understand the effects of changes in one of these parameters on the other. Is it possible to monitor only the beam flatness and not PDD? The investigation has two components. Naturally occurring i.e., unintended changes in PDD ratio and in-plane flatness for 6 and 10 MV photon beams for one particular Siemens Artiste Linac are monitored for a period of about 4 years. Secondly, deliberate changes in the beam parameters are induced by changing the bending magnet current (BMI). Relationships between various beam parameters for unintended changes as well as deliberate changes are characterized. Long term unintentional changes of PDD ratio are found to have no systematic trend. The flatness in the inplane direction for 6 and 10 MV beams show slow increase of 0.43 and 0.75% respectively in about 4 years while the changes in the PDD ratio show no such trend. Over 10% changes in BMI are required to induce changes in the beam quality indices at 2% level. PDD ratio for the 10 MV beam is found to be less sensitive, while the depth of maximum dose, d(max), is more sensitive to the changes in BMI compared to the 6 MV beam. Tolerances are more stringent for PDD10 than PDD ratio for the 10 MV beam. PDD ratio, PDD10, and flatness must be monitored independently. Furthermore, off axis ratio alone cannot be used to monitor flatness. The effect of beam quality change in the absolute dose is clinically insignificant.

Output variation from an intensity modulating dynamic collimator.

Intensity modulated radiation therapy (IMRT) offers a method of delivering radiation dose conforming to the shape of targets while minimizing the dose to the surrounding tissue and nearby critical organs. One popular device is the NOMOS MIMiC Collimator coupled to the CORVUS treatment planning system. The MIMiC collimator, mounted on a linac head, opens and closes one or more of its 40 small leaves as determined by the planner while the linac delivers radiation and the gantry rotates. This dynamic IMRT allows the intensity to be modulated yielding a highly conformal dose distribution. However, the dose output becomes a function of the detailed manner in which the leaves open and close, since the opening and closing are not instantaneous. We investigate the effect of switch rates and delay in the open/close events on the output profiles. The output is enhanced as the switch rate increases. The enhancement factor at any point of measurement is dependent on its distance from the central plane. We interpret these variations in terms of a simple model, which includes the effect of leaf travel time during the process of opening and closing. We also include the time delay in establishing the specified pressure in the pneumonic device, which controls the opening and closing of the leaves. The information presented here offers a means for incorporating these output changes into the planning system. This may avoid the current situation where many patient plans need to be renormalized based on the actual measurement taken during the delivery of the specified intensity pattern to a phantom.

Planning target volume-to-skin proximity for head-and-neck intensity modulated radiation therapy treatment planning.

PURPOSE: The goal of this work is to evaluate planning target volume (PTV)-to-skin proximity versus plan quality as well as the effects of calculation voxel size on dose uncertainty in the surface region. METHODS AND MATERIALS: A right-sided clinical target volume with the lateral border 5 mm from the surface was delineated on the computed tomographic data of a head-and-neck phantom. A 5-mm PTV expansion was generated except laterally where distances of 0-5 mm were used. A 7-field intensity modulated radiation therapy plan was generated using the Eclipse treatment planning system. Optimization was performed where 95% of the PTV receives the prescription dose using a voxel size of 2 mm(3). Dose calculations were repeated for voxel sizes of 1, 3, and 5 mm(3). For each plan, 9 point dose values were obtained just inside the phantom surface, corresponding to a 2 cm × 2 cm grid near the central target region. Nine ultrathin thermoluminescent dosimeters were placed on the phantom surface corresponding to the grid. Measured and calculated dose values were compared. Conformality, homogeneity, and target coverage were compared as well. This process was repeated for volumetric modulated arc therapy (VMAT) calculated with a 2-mm(3) voxel size. RESULTS: Surface dose is overestimated by the treatment planning system (TPS) by approximately 21% and 9.5% for 5- and 3-mm(3) voxels, respectively, and is accurately predicted for 2-mm(3) voxels. A voxel size of 1 mm(3) results in underestimation by 11%. Conformality improves with increasing PTV-to-skin distance and a conformality index of unity is obtained for grid sizes between 1 and 3 mm(3) and PTV-to-skin distances of 4-4.5 mm. Hot spot also improves and falls below 110% at 4-mm PTV-to-skin distance. Underdosage worsens as the PTV approaches the skin. All of the above appear to hold for volumetric modulated arc therapy. CONCLUSIONS: For decreasing PTV-to-skin distance with this TPS, isodose conformality decreases, "hot spot" increases, and target coverage degrades. Surface dose is overestimated when voxel sizes greater than 2 mm(3) are chosen, and underestimated for smaller voxels.

Effect of gold marker seeds on magnetic resonance spectroscopy of the prostate.

PURPOSE: Magnetic resonance stereoscopic imaging (MRSI) of the prostate is an emerging technique that may enhance targeting and assessment in radiotherapy. Current practices in radiotherapy invariably involve image guidance. Gold seed fiducial markers are often used to perform daily prostate localization. If MRSI is to be used in targeting prostate cancer and therapy assessment, the impact of gold seeds on MRSI must be investigated. The purpose of this study was to quantify the effects of gold seeds on the quality of MRSI data acquired in phantom experiments. METHODS AND MATERIALS: A cylindrical plastic phantom with a spherical cavity 10 centimeters in diameter wss filled with water solution containing choline, creatine, and citrate. A gold seed fiducial marker was put near the center of the phantom mounted on a plastic stem. Spectra were acquired at 1.5 Tesla by use of a clinical MRSI sequence. The ratios of choline + creatine to citrate (CC/Ci) were compared in the presence and absence of gold seeds. Spectra in the vicinity of the gold seed were analyzed. RESULTS: The maximum coefficient of variation of CC/Ci induced by the gold seed was found to be 10% in phantom experiments at 1.5 T. CONCLUSION: MRSI can be used in prostate radiotherapy in the presence of gold seed markers. Gold seeds cause small effects (in the order of the standard deviation) on the ratio of the metabolite's CC/Ci in the phantom study done on a 1.5-T scanner. It is expected that gold seed markers will have similar negligible effect on spectra from prostate patients. The maximum of 10% of variation in CC/Ci found in the phantom study also sets a limit on the threshold accuracy of CC/Ci values for deciding whether the tissue characterized by a local spectrum is considered malignant and whether it is a candidate for local boost in radiotherapy dose.